

PatentSight Webinar

# **Where do we stand in fighting pandemics caused by bacteria?**

A closer look into the patent landscape of antibiotics

## Presenters



**Gene Quinn**

President & CEO  
IPWatchdog, Inc.



**Dr. Sarbani  
Chattopadhyay**

Consultant  
at PatentSight –  
A LexisNexis Company



**Dr. Dirk Caspary**

Senior Consultant  
at PatentSight –  
A LexisNexis Company

# The Importance of Developing New Antibiotics and Therapies

## 2019 ANTIBACTERIAL AGENTS IN CLINICAL DEVELOPMENT

an analysis of the antibacterial clinical development pipeline




## ANTIBACTERIAL AGENTS IN PRECLINICAL DEVELOPMENT


an open access database




## The Antibiotics and Bacteriophages Portfolio Sizes Over the Last 20 Years





# The In Force-to-Pending Ratio of Antibiotic Patents



# Top 10 Antibiotics Patent Owners




# Our Approach



# The WHO Priority List


- **Tuberculosis (TB)** is the number one global infectious disease killer today, causing 1.8 million deaths per year.
- Drug-resistant tuberculosis is the most common and lethal airborne antimicrobial resistance (AMR) disease with 250,000 deaths each year.
- Only 52 % of patients with multidrug-resistant tuberculosis (MDR-TB) are successfully treated globally.
- In about 50% of MDR-TB patients worldwide, treatment regimens are already compromised by second-line drug resistance.
- Treatment of extensively drug-resistant disease (XDR-TB2) is successful in only one in three patients at best.




Source: WHO, "2019 Antibacterial agents in clinical development - An analysis of the antibacterial clinical development pipeline"



# The Competitive Impact™ Trend for Tuberculosis Antibiotics




# Owners of Recent New Antibiotics Against the WHO Priority Pathogens\*




\* Market authorization between 06/17 and 09/19

# Owners of Recent New Antibiotics Against the WHO Priority Pathogens\*




\* Market authorization between 06/17 and 09/19

# The Competitive Impact™ Trend for WHO Priority Pathogen Antibiotics



# The Competitive Impact™ Trend for WHO Priority Pathogen Antibiotics



# Seminar: “Business Opportunities and Insights from Patent Analytics”

Register for our upcoming September and October Virtual Innovation Analytics Academy Seminars

## Use this opportunity to:

- Increase your knowledge in patent analytics
- Operate the Business Intelligence Analytics
- Interpret the patent analytics' results
- Network with other patent professionals
- Boost your career with customized training



[More Info, Dates & Registration](#)



# Join our free PatentSight Coffee Break Sessions!



**Our expert presenters provide you with unique information on global innovation topics:**

- What are the current and future trends in pharma?
- Which new players entered the market?
- Who will be dominating the industry in different pharmaceutical technology fields?


[More Info, Dates & Registration](#)




# More about Advanced Analytics with PatentSight


Click to download whitepaper




 The Patent Landscape of Artificial Intelligence




 The Landscape of Machine Learning from a Patent Perspective




 Looking into the Digital Crystal Ball




 Early Identification of Disruptive Players with Advanced Patent Analytics



 Merger Deals Increasingly Scrutinized Using Patent Analysis



 Digital Aliens in Autonomous Driving

Visit: [www.patentsight.com](http://www.patentsight.com)

Schedule a demo at: [www.patentsight.com/demo](http://www.patentsight.com/demo)

Find information about our patent analytics seminars at: [www.innovation-analytics.com](http://www.innovation-analytics.com)



# Our Product Range

Product	<b>PatentSight Analytics Platform</b>	<b>PatentSight Datasets</b>	<b>PatentSight Expert Analyses</b>
Features	Leading innovation analytics platform (software-as-a-service); Powerful data analysis and visualization capabilities	Global patent datasets with unique innovation KPIs; mapped to financial IDs for direct inclusion into data feed	Comprehensive IP analyses conducted by our inhouse patent expert team with longstanding experience
Target Customers	IP professionals; R&D teams; Strategic and Competitive Intelligence professionals; Discretionary investors	Quantitative investors	IP professionals; R&D teams; Private equity investors and M&A advisors
Use Cases	Portfolio Management; R&D Strategy; M&A; Benchmarking; Licensing, Trend Scouting	Stock Valuation; Creation of trading signals	Benchmarking, Internationalization Strategies; Portfolio Interrelationships Target search; Due Diligence
Pricing	Per License	Per Dataset	Per Project



---

**Thank you**

**[www.patentsight.com](http://www.patentsight.com)  
[info@patentsight.com](mailto:info@patentsight.com)**

**PatentSight GmbH  
Joseph-Schumpeter Allee 33  
53227 Bonn, Germany**